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Long-Term Clinical Efficacy of Immunotherapy in Rhino-Conjunctivitis with Pollen Extract
Carlos Nunes, and Susel Ladeira,. Center of Allergy of Algarve, Portimao, Portugal. Background: Evaluate long-term clinical efficacy 2 years after suspension of specific immunotherapy in patients with seasonal rhino-conjunctivitis. Methods: During 5 years in a pre-seasonal period an extract of 7 grass pollens by sub cutaneous route (SCIT) was administered to a group of 16 patients with moderate and severe rhino-conjunctivitis, monosensitised to grass pollens. The mean age of the patients was 27.1 years, with homogeneous sex distribution. After the terminus of SCIT the group was followed during 2 more years to evaluate symptomatology and the use of rescue medication, during pollen season. We have compared this group with another group who did not perform SCIT. All patients received weekly information about forecasts and grass pollens count in their residential area. An informatics sheet was used to evaluate daily 4 degrees of 6 parameters including nasal and eye symptoms and any use of medication used to control the disease. As statistical method ANOVA test and t test was used for analyse mean differences between the 2 groups. For correlations the Spearman method was used. Results: During the immediate 2 years after SCIT in the active group, a significant reduction on symptoms (42%) as well as a reduction on the use of rescue medication (59%) were observed (P , 0.01), compared with the control group. The eye symptoms had a higher reduction than nasal symptoms after the suspension of IT. Conclusions: A significant efficacy of SCIT was verified even 2 years after the suspension of the treatment, with reduction on symptoms and on use of medication. The use of a daily score of symptoms and the use of rescue medication was very useful and confortable to the majority of the patients. Also providing regular information to patients regarding pollen count and climatic changes by electronic mail was considered useful to both groups. Alllergy, "Joaquin Albarran" Hospital, Havana, Cuba. Background: Allergen immunotherapy (AIT) induces IgG4 antibodies with blocking effect, and long-term reduction of IgE. The problem of finding suitable surrogate paraclinical markers during AIT is currently very relevant. The aim was to evaluate the allergen-specific IgE/IgG4 ratio as an immunological correlate to clinical efficacy during AIT with House Dust Mite (HDM) allergen vaccines in Cuban asthmatic patients. Methods: Three separate Double-Blind Placebo-Controlled clinical trials of AIT were performed using standardized registered allergen extracts of 3 HDM species: Dermatophagoides pteronyssinus, and the tropical species D. siboney and Blomia tropicalis. Each clinical trial included 40 asthmatic patients, totalling 120 individuals. Half of them received placebo. Allergenspecific IgE and IgG4 antibodies were measured by ELISA. Antibody titres were normalized and averaged between the 3 trials. Size effect was calculated as the Standard Mean Difference (SMD) between the active and placebo groups, using meta-analysis tools. Results: There was a significant increase of IgG4 antibodies (P , 0.05) after 6 months of treatment. At 12 months, the IgG4 increase was even greater and the IgE decrease achieved also significance (P , 0.05). Thus, IgG4 induction appeared to precede IgE changes, in agreement with the possible role of the Treg/IL-10 response induction at the initial AIT phase. Moreover, 83% of patients showed a decrease of the IgE/IgG4 ratio in the active groups, whereas only 32% showed reduction in placebo groups. The IgE/IgG4 ratio was the immunological variable with the greatest size effect value (SMD ¼ 0.81 95% CI, 0.71-0.91), as compared to changes in IgE or IgG4 levels, alone. The size effect value was close to the clinical effect (symptom-medication score SMD ¼ 1.2 95% CI, 0.7-1.7). Per-patient changes in IgG4 levels, as well as, in the IgE/IgG4 ratio, were significantly correlated to the symptom-medication variable (r ¼ 0.23, P ¼ 0.04). Conclusions: These results support the use of the IgE/IgG4 ratio as an easily measurable marker for monitoring the allergen-specific immunity during AIT with HDM in asthmatic patients, and possibly, for predicting patient's clinical improvement after 1 year of treatment.
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